Navigation Links
Pretreatment PET/CT imaging of lymph nodes predicts recurrence in breast cancer patients
Date:9/4/2012

Disease-free survival for invasive ductal breast cancer (IDC) patients may be easier to predict with the help of F-18-fludeoxyglucose positron emission tomography (PET)/computed tomography (CT) scans, according to research published in the September issue of The Journal of Nuclear Medicine. New data show that high maximum standard uptake value (SUVmax) of F-18-FDG in the lymph nodes prior to treatment could be an independent indicator of disease recurrence.

"Many studies have revealed that breast cancer patients with axillary lymph node metastasis have a significantly poorer prognosis than those without nodal metastases," noted Sang-Woo Lee, MD, PhD, one of the authors of "F-18-FDG Uptake by Metastatic Axillary Lymph Nodes on Pretreatment PET/CT as a Prognostic Factor for Recurrence in Patients with Invasive Ductal Breast Cancer." "However, the prognostic value of F-18-FDG uptake in metastatic axillary lymph nodes with PET/CT has not been investigated in IDC patients," he added.

In the study, researchers followed 65 female patients with IDC who had undergone pretreatment F-18-FDG PET/CT and who had pathologically confirmed axillary lymph node involvement without distant metastases. Factors such as age, TNM (tumor, lymph node and metastases) stage, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status, and SUVmax for the primary-tumor and axillary lymph nodes were analyzed. Patients underwent treatment and were followed for a range of 21-57 months (median of 36 months).

Among the patients, 53 were disease-free and 12 had disease recurrence during the follow-up period. While both the primary-tumor and nodal SUVmax were higher in patients with recurrence, the nodal SUVmax was significantly higher. In addition, compared to the other factors that were analyzed, only nodal SUVmax was found to be an independent determinant of disease-free survival. Using a receiver-operating-characteristic curve, the researchers demonstrated that a nodal SUVmax of 2.8 was the optimal cutoff for predicting disease-free survival.

"One of the important roles of molecular imaging in cancer research is to noninvasively predict precise prognosis. Our results showed significant improvement in the accuracy of risk prediction for disease-free survival rates when nodal SUVmax was added to well-known established risk factors," said Lee. "Our study suggests that 18F-FDG PET/CT could yield useful information for risk stratification and treatment strategies in IDC patients with axillary lymph node involvement."

An estimated one in eight women will develop breast cancer in her lifetime. According to the American Cancer Society, an estimated 280,000 new cases of breast cancer were diagnosed among women in 2011, and nearly 40,000 died from the disease.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Benefit of PET and PET/CT in ovarian cancer is not proven
2. Study examines necessity of additional imaging in PET/CT oncologic reports
3. Non-invasive diagnostic imaging costs to Medicare Part B down significantly since 2006
4. Accuracy of narrow band imaging with colonoscopy allows for distal non-cancerous polyps to be left in place
5. ASGE initiative examines real-time imaging of Barretts esophagus
6. Theranostic imaging offers means of killing prostate cancer cells
7. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
8. Imaging Tests Up Among Advanced Cancer Patients
9. Diagnostic imaging increases among stage IV cancer patients on Medicare
10. ACR: Medical imaging study in health affairs incomplete and potentially misleading
11. Fighting obesity with thermal imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... Pregnancy Awareness Month offers a great time to get familiar ... you are ready to have a baby, it’s best to get started before age ... your Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a ... designed to automate and improve the rapid diagnosis, triage and admission of patients ... platform, application, and mobile experience for the first time at GENBAND’s Perspectives16 conference. ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... EVP and GM Jim Callandrillo and Duane Reed, VP of business development ... Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting from May 15-17 ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased to ... Could Transform the Pharma Landscape .” CMS recently proposed a test of alternate payment ... drugs while preserving care provided to beneficiaries. The webinar will review the details of ...
(Date:5/2/2016)... ... 2016 , ... For many artists, the act of blending paint is based ... a science. , Using the new, highly precise METTLER TOLEDO ML204T balance to ... and meaning to his works. What’s more, it has allowed him to recreate these ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 Glycotope GmbH, a ... announces the appointment of Dr. Alfredo Zurlo ... an oncologist with many years clinical experience and a ... His last role was at Mologen AG where he ... Board. Previously Dr. Zurlo held various positions at F ...
(Date:4/28/2016)... 2016   Click here for supplemental information ... DPLO), the nation,s largest independent specialty pharmacy, announced ... to acquire Valley Campus Pharmacy, Inc., doing business ... specialty pharmacy that provides individualized patient care, based ... In 2015, TNH generated approximately $400 million in ...
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
Breaking Medicine Technology: